Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367312658> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4367312658 endingPage "254" @default.
- W4367312658 startingPage "248" @default.
- W4367312658 abstract "In 2018, Anavip became available for the treatment of rattlesnake envenomations in the USA. No comparisons between the treatment characteristics of patients have been made since Anavip and CroFab have both been widely available. The objective of this study was to compare the number of antivenom vials administered of CroFab and Anavip during the treatment of rattlesnake envenomations in the USA.This was a secondary analysis of rattlesnake envenomations utilizing the North American Snakebite Registry (NASBR) from 2019 through 2021. Frequencies and proportions were used to summarize demographics and baseline clinical characteristics. The primary outcome was total antivenom vials administered during treatment. Secondary outcomes included the number antivenom administration events, total treatment time, and hospital length of stay.Two hundred ninety-one rattlesnake envenomations were analyzed; most occurred in the Western USA (n = 279, 96 %). One hundred one patients (35%) received only CroFab, 110 (38%) received Anavip only, and 80 (27%) received both products. The median number of vials used was 10 for CroFab, 18 for Anavip, and 20 for both antivenoms. More than one antivenom administration was necessary in thirty-nine (39%) patients that received only CroFab and 76 (69%) patients that received Anavip only. The median total treatment time was 5.5 hours for CroFab, 6.5 for Anavip, and 15.5 hours when both antivenoms were administered. All antivenom groups had a median hospital length of stay of 2 days.Rattlesnake envenomated patients in the Western USA treated with CroFab had fewer antivenom vials and fewer antivenom administrations compared to patients treated with Anavip." @default.
- W4367312658 created "2023-04-29" @default.
- W4367312658 creator A5014870395 @default.
- W4367312658 creator A5024905684 @default.
- W4367312658 creator A5028892607 @default.
- W4367312658 creator A5056542161 @default.
- W4367312658 creator A5057826545 @default.
- W4367312658 date "2023-04-28" @default.
- W4367312658 modified "2023-09-30" @default.
- W4367312658 title "Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019–2021" @default.
- W4367312658 cites W1535399514 @default.
- W4367312658 cites W1988619378 @default.
- W4367312658 cites W2012220123 @default.
- W4367312658 cites W2108738255 @default.
- W4367312658 cites W2121408958 @default.
- W4367312658 cites W2125873511 @default.
- W4367312658 cites W2128425068 @default.
- W4367312658 cites W2133264563 @default.
- W4367312658 cites W2764235717 @default.
- W4367312658 cites W2891885419 @default.
- W4367312658 cites W3000147729 @default.
- W4367312658 cites W3082314070 @default.
- W4367312658 cites W3109020898 @default.
- W4367312658 cites W4206964012 @default.
- W4367312658 cites W4290737583 @default.
- W4367312658 doi "https://doi.org/10.1007/s13181-023-00941-7" @default.
- W4367312658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37115482" @default.
- W4367312658 hasPublicationYear "2023" @default.
- W4367312658 type Work @default.
- W4367312658 citedByCount "1" @default.
- W4367312658 countsByYear W43673126582023 @default.
- W4367312658 crossrefType "journal-article" @default.
- W4367312658 hasAuthorship W4367312658A5014870395 @default.
- W4367312658 hasAuthorship W4367312658A5024905684 @default.
- W4367312658 hasAuthorship W4367312658A5028892607 @default.
- W4367312658 hasAuthorship W4367312658A5056542161 @default.
- W4367312658 hasAuthorship W4367312658A5057826545 @default.
- W4367312658 hasBestOaLocation W43673126581 @default.
- W4367312658 hasConcept C117287731 @default.
- W4367312658 hasConcept C141071460 @default.
- W4367312658 hasConcept C145600735 @default.
- W4367312658 hasConcept C147789679 @default.
- W4367312658 hasConcept C185592680 @default.
- W4367312658 hasConcept C18903297 @default.
- W4367312658 hasConcept C194828623 @default.
- W4367312658 hasConcept C2779448229 @default.
- W4367312658 hasConcept C71924100 @default.
- W4367312658 hasConcept C72092618 @default.
- W4367312658 hasConcept C86803240 @default.
- W4367312658 hasConceptScore W4367312658C117287731 @default.
- W4367312658 hasConceptScore W4367312658C141071460 @default.
- W4367312658 hasConceptScore W4367312658C145600735 @default.
- W4367312658 hasConceptScore W4367312658C147789679 @default.
- W4367312658 hasConceptScore W4367312658C185592680 @default.
- W4367312658 hasConceptScore W4367312658C18903297 @default.
- W4367312658 hasConceptScore W4367312658C194828623 @default.
- W4367312658 hasConceptScore W4367312658C2779448229 @default.
- W4367312658 hasConceptScore W4367312658C71924100 @default.
- W4367312658 hasConceptScore W4367312658C72092618 @default.
- W4367312658 hasConceptScore W4367312658C86803240 @default.
- W4367312658 hasIssue "3" @default.
- W4367312658 hasLocation W43673126581 @default.
- W4367312658 hasLocation W43673126582 @default.
- W4367312658 hasOpenAccess W4367312658 @default.
- W4367312658 hasPrimaryLocation W43673126581 @default.
- W4367312658 hasRelatedWork W1691695585 @default.
- W4367312658 hasRelatedWork W1993830528 @default.
- W4367312658 hasRelatedWork W2081089917 @default.
- W4367312658 hasRelatedWork W2120895028 @default.
- W4367312658 hasRelatedWork W2403666733 @default.
- W4367312658 hasRelatedWork W3003947745 @default.
- W4367312658 hasRelatedWork W3036941205 @default.
- W4367312658 hasRelatedWork W3175895229 @default.
- W4367312658 hasRelatedWork W3186259937 @default.
- W4367312658 hasRelatedWork W4220854187 @default.
- W4367312658 hasVolume "19" @default.
- W4367312658 isParatext "false" @default.
- W4367312658 isRetracted "false" @default.
- W4367312658 workType "article" @default.